WebNov 18, 2013 · On November 13, 2013, Titan Pharmaceuticals (NASDAQ:NASDAQ:TTNP) announced a restructuring of the Probuphine commercialization agreement with Braeburn Pharmaceuticals Sprl whereby Braeburn... Web• Buprenorphine implant (Probuphine®, Braeburn/Titan, FDA approved May 26, 2016) 20 • Buprenorphine subcutaneous extended-release injection (CAM2038, Braeburn, investigational, additional information will be submitted for FDA review) 21. There is interest in understanding whether these new delivery mechanisms might expand access to
Titan Pharmaceuticals Inc (TTNP): …
WebApr 12, 2024 · Just prior to Titan’s announcement, the FDA issued a Complete Response Letter (CRL) for CAM2038, Braeburn’s lead development candidate for the treatment of adults with opioid abuse disorder. WebThe live webcast of the call may be accessed by visiting the Events page on Titan's website. The call can also be accessed by dialing 1-855-940-9476 (or 1-412-317-5223 … cute hairstyles with french braids
Titan Pharmaceuticals And Braeburn Announce Mutual …
WebUnder its current agreement with Braeburn, Titan is eligible to receive a milestone payment of $15 million upon FDA approval. Once the product is on the market, Titan will receive a royalty on ... WebBraeburn has paid Titan $1 million and will provide assistance to Titan through December 28, 2024 to enable a smooth transition and ensure that patients and their doctors will continue to have support and access to this treatment. In addition, the parties will immediately transfer to Titan all regulatory documentation and development data ... WebDecember 31, 2024, providing some breathing room for Titan to get Probuphine back on track. 2024 Financial Results For 2024 Titan reported total revenues of $215 thousand increasing from $65 thousand in 2016. Full year research and development costs totaled $9.6 million, rising 57%. The expansion was due to external research and cute hairstyles with gel